Core Technology

GeneQuantum's foundational strength lies in its proprietary enzymatic conjugation platform, which differentiates it from many other ADC developers. Traditional ADCs are often produced through chemical conjugation methods that link payloads to antibodies at random sites, resulting in heterogeneous mixtures of drug-to-antibody ratios (DAR). This heterogeneity can affect the pharmacokinetics, efficacy, and safety of the final product.

Intelligent Ligase-Dependent Conjugation (iLDC)

The company's signature technology is its Intelligent Ligase-Dependent Conjugation platform, often referred to as iLDC. This approach uses naturally occurring or engineered enzymes (ligases) to attach payloads to antibodies at defined, specific sites. The benefits of this enzymatic, site-specific approach include:

• Highly homogeneous products with precisely controlled drug-to-antibody ratios
• Improved stability of the linker-payload connection
• Greater consistency and reproducibility in manufacturing
• Potential for a wider therapeutic window compared with conventionally conjugated ADCs

GQ-Link and Conjugation Toolbox

Supporting the iLDC platform, GeneQuantum has developed a suite of linker and conjugation technologies designed to optimize the way payloads are connected to antibodies and other carrier molecules. These tools allow the company to tune the properties of its conjugates, including the cleavability of the linker, the release of the payload inside target cells, and the overall pharmacological behavior of the molecule.

The platform is designed to be modular and flexible, enabling application not only to antibody-drug conjugates but also to a broader range of bioconjugates, including peptide-drug conjugates and other targeted delivery systems.

Pipeline and Products

GeneQuantum is developing a pipeline of proprietary ADC candidates targeting various solid tumors and hematological malignancies. The company pursues both internally developed programs and collaborations with other pharmaceutical and biotechnology companies.

Lead Programs

The company's most advanced candidates target validated and emerging tumor antigens. Among its programs is a HER2-directed antibody-drug conjugate aimed at HER2-expressing cancers, a target relevant to breast, gastric, and other solid tumors. The company has also worked on candidates directed at other clinically significant targets in oncology.

These programs leverage the iLDC platform to produce conjugates with well-defined DAR profiles and improved manufacturability, with the goal of achieving better outcomes for patients compared with existing therapies.

Partnered and Out-Licensed Programs

GeneQuantum has entered into partnerships and licensing arrangements with both domestic and international pharmaceutical companies. Through these collaborations, the company applies its conjugation technology to partners' antibodies and payloads, generating novel ADC candidates. Such arrangements typically involve upfront payments, development and regulatory milestones, and royalties on future product sales, providing the company with non-dilutive funding and validation of its technology platform.

Services and Business Model

Beyond its internal drug development, GeneQuantum offers technology-enabled collaboration and services centered on its conjugation expertise. These include:

• Technology licensing of its enzymatic conjugation and linker platforms to partners developing their own bioconjugates
• Co-development of ADC and bioconjugate candidates using partner-supplied antibodies or payloads
• Research collaborations to explore novel targets and conjugation strategies

This dual approach—advancing a proprietary pipeline while monetizing its platform through partnerships—allows the company to diversify its revenue sources and accelerate the broader adoption of its conjugation technology.

Therapeutic Focus

The company's primary therapeutic focus is oncology, where targeted delivery of cytotoxic payloads offers the potential to kill cancer cells while sparing healthy tissue. Antibody-drug conjugates have become one of the fastest-growing modalities in cancer treatment, and GeneQuantum aims to contribute to this field by improving the precision and quality of conjugate manufacturing.

By focusing on homogeneity and stability, the company seeks to address common challenges in ADC development, such as off-target toxicity, premature payload release, and batch-to-batch variability.

Location and Operations

GeneQuantum is headquartered in Suzhou, within the Jiangsu Province of China, a region that has become a major hub for biotechnology and pharmaceutical innovation. The Suzhou area, particularly its biomedical industrial parks, hosts numerous life sciences companies and offers access to research talent, infrastructure, and a supportive ecosystem for drug development.

The company maintains research and development laboratories along with process development and manufacturing capabilities suited to producing bioconjugates under quality-controlled conditions.

Significance and Outlook

GeneQuantum represents part of a broader wave of Chinese biotechnology companies that are developing innovative therapeutic modalities and competing on the global stage. Its emphasis on enzymatic, site-specific conjugation technology addresses a recognized need in the ADC industry for more homogeneous and reliably manufactured products.

As the demand for antibody-drug conjugates and other targeted therapies continues to grow, companies with differentiated conjugation platforms are positioned to play an important role in shaping the future of precision oncology. Through its combination of proprietary technology, an evolving clinical pipeline, and strategic partnerships, GeneQuantum continues to pursue its mission of advancing next-generation bioconjugate therapeutics for patients with serious diseases.